CN1200710C - 大环内酯类化合物的新用途 - Google Patents

大环内酯类化合物的新用途 Download PDF

Info

Publication number
CN1200710C
CN1200710C CNB008105898A CN00810589A CN1200710C CN 1200710 C CN1200710 C CN 1200710C CN B008105898 A CNB008105898 A CN B008105898A CN 00810589 A CN00810589 A CN 00810589A CN 1200710 C CN1200710 C CN 1200710C
Authority
CN
China
Prior art keywords
chemical compound
hemorrhage
brain injury
ischemia
cerebral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008105898A
Other languages
English (en)
Chinese (zh)
Other versions
CN1361691A (zh
Inventor
P·A·琼斯
J·沙基
J·S·凯利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of CN1361691A publication Critical patent/CN1361691A/zh
Application granted granted Critical
Publication of CN1200710C publication Critical patent/CN1200710C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
CNB008105898A 1999-07-21 2000-07-19 大环内酯类化合物的新用途 Expired - Fee Related CN1200710C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9917158.9 1999-07-21
GBGB9917158.9A GB9917158D0 (en) 1999-07-21 1999-07-21 New use

Publications (2)

Publication Number Publication Date
CN1361691A CN1361691A (zh) 2002-07-31
CN1200710C true CN1200710C (zh) 2005-05-11

Family

ID=10857695

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008105898A Expired - Fee Related CN1200710C (zh) 1999-07-21 2000-07-19 大环内酯类化合物的新用途

Country Status (15)

Country Link
US (1) US20060287353A1 (ko)
EP (1) EP1196170B1 (ko)
JP (1) JP2003504396A (ko)
KR (1) KR100508623B1 (ko)
CN (1) CN1200710C (ko)
AT (1) ATE270888T1 (ko)
AU (1) AU6003900A (ko)
CA (1) CA2379140A1 (ko)
DE (1) DE60012183T2 (ko)
DK (1) DK1196170T3 (ko)
ES (1) ES2220492T3 (ko)
GB (1) GB9917158D0 (ko)
HK (1) HK1047704B (ko)
PT (1) PT1196170E (ko)
WO (1) WO2001005385A2 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035411A1 (es) * 2000-12-29 2004-05-26 Fujisawa Pharmaceutical Co Uso de un derivado de tacrolimus para fabricar un agente neurotrofico, composiciones y articulos de fabricacion o kits que lo comprenden, metodo para fabricar un agente que lo comprende y tejidos e injertos con una celula nerviosa tratada con este compuesto
AU2003901023A0 (en) * 2003-03-04 2003-03-20 Fujisawa Pharmaceutical Co., Ltd. New use
CA2554045A1 (en) * 2004-01-20 2005-07-28 Astellas Pharma Inc. Method for treating erectile dysfunction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB8728820D0 (en) * 1987-12-09 1988-01-27 Fisons Plc Compounds
GR1001225B (el) * 1989-09-14 1993-06-30 Fisons Plc Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους.
GB9202196D0 (en) * 1992-02-01 1992-03-18 Fisons Plc Method of treatment
GB9218027D0 (en) * 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
GB9227055D0 (en) * 1992-12-29 1993-02-24 Fujisawa Pharmaceutical Co New use

Also Published As

Publication number Publication date
PT1196170E (pt) 2004-10-29
JP2003504396A (ja) 2003-02-04
KR100508623B1 (ko) 2005-08-17
DK1196170T3 (da) 2004-08-30
GB9917158D0 (en) 1999-09-22
KR20020060148A (ko) 2002-07-16
DE60012183T2 (de) 2004-11-18
ATE270888T1 (de) 2004-07-15
AU6003900A (en) 2001-02-05
HK1047704B (zh) 2005-12-16
EP1196170B1 (en) 2004-07-14
US20060287353A1 (en) 2006-12-21
CA2379140A1 (en) 2001-01-25
ES2220492T3 (es) 2004-12-16
DE60012183D1 (de) 2004-08-19
HK1047704A1 (en) 2003-03-07
CN1361691A (zh) 2002-07-31
EP1196170A2 (en) 2002-04-17
WO2001005385A2 (en) 2001-01-25
WO2001005385A3 (en) 2001-08-02

Similar Documents

Publication Publication Date Title
US20170360798A1 (en) Anavex2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection
US9107925B2 (en) Sodium channel blocker for treatment of loss of superficial sensitivity
US20210077487A1 (en) Pharmaceutical composition containing hdac6 inhibitor as active ingredient for prevention or treatment of itching
CN104619710A (zh) 用于治疗再灌注损伤的氧杂二环庚烷和氧杂二环庚烯
KR100535554B1 (ko) 소아과 수술에서의 레보부피바카인의 용도
JP3623501B2 (ja) インターロイキン−１阻害化合物による神経病学的状態の治療
CN1200710C (zh) 大环内酯类化合物的新用途
EP2190430A1 (de) Verwendung von von cycloheximid abgeleiteten verbindungen zur behandlung oder vorbeugung von insbesondere ischämien und herzerkrankungen
JPH0320222A (ja) 脳内虚血症治療剤
DE69814089T2 (de) Verwendung von einem draflazin analog zur schmerzbehandlung
SK280111B6 (sk) Použitie ropivakaínu na výrobu farmaceutického pro
EP0305181A2 (en) Ethyl-(+)-apovincaminate for treating demyelinization clinical patterns of autoimmune origin
Shelton et al. Simulated abuse of tybamate in man: Failure to demonstrate withdrawal reactions
JPH04338328A (ja) 血管形成阻害剤として有用なベンゾイルカルビノール及びそのエステル
EP1603583A2 (de) Verwendung von weihrauch oder seinen hydrierungsprodukten zur prophylaxe und/oder behandlung von zerebraler ischemie und/oder schedel/hirntrauma
US6784194B2 (en) Therapeutic use of a thienylcyclohexylamine derivative
EP1091750B1 (en) Cerebrospinal and vascular pharmaceutical composition and process for preparing the same
IL93243A (en) Preparations for the prevention of neurodegeneration
KR102118227B1 (ko) 척추 투여용 과포화 아세타미노펜 주사 용액
JPH07126162A (ja) アスコルビン酸類の脳内投与剤
KR100413717B1 (ko) 레보부피바카인및임산부의마취제로서그것의용도
Means 21-Aminosteroids (“Lazaroids”)
JPH09227381A (ja) 脳血栓における運動麻痺の改善剤
UA146317U (uk) Лікарський засіб в парентеральній лікарській формі
Means Clinical Research II The Upjohn Company 526 Jasper St. Kalamazoo, MI 49007

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: ASTELLAS PHARMA INC.

Free format text: FORMER NAME OR ADDRESS: FUJISAWA PHARMACEUTICAL CO., LTD.

CP03 Change of name, title or address

Address after: Tokyo, Japan

Patentee after: Yamanouchi Pharma Co., Ltd.

Address before: Osaka City, Osaka of Japan

Patentee before: Fujisawa Pharmaceutical Co., Ltd.

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee